Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors

Does Carboplatin Rapid Desensitization Change Its Adverse Drug Reactions Other than Hypersensitivity and Efficacy in Patients With Ovarian Cancer?

“… 8 33 34 Carboplatin infusion through RDD was reported to cause grade 2 or higher BTR in 5% to 10%. 7 35 36 37 According to Sloane et al , 8 the BTR results of 1,069 desensitization therapies of carboplatin showed a similar rate to the BTR results of our study. It was also demonstrated in this study that the risk of BTR decreases as the number of desensitization therapies is repeated.…”

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

“…[2-22.8]). Kang et al [138]in a series of 234 RDD with several ChDs and mAbs using the 3bag/12-steps protocol found, conversely to other series, that BTR development was associated with the severity of the initial reaction and the administration of previous cycles of the same drug. Indeed, the severity of these BTR was related with these two factors and also with a positive history of drug allergy.…”

“…A common finding in the RDD to ChD and mAb series is the high success rate and both the low number and severity of BTR [5,14,21,70,88,121,138]. However, despite being generally mild, there is still up to 25% of reactions [5,14,21,70,88,121,138]. Different risk factors have been described that partially differ from one series to another, as discussed below.…”

Rapid protocol for irinotecan desensitization: a case report and literature review

“…Although the molecular basis of this desensitization remains incompletely understood, the most likely hypothesis is that RDD inhibits mast cell activation. However, as in our case, the occurrence of breakthrough adverse reactions (BTRs) during RDD are reported in 10-40% of cases [2,5] and their severity is significantly associated with initial HSRs severity, history of drug allergy and previous exposure to chemotherapeutic agents. The BTRs, instead, do not seem to be related to type and dose of premedication.…”